Vancomycin-Resistant Enterococcus faecium Infections – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Vancomycin-Resistant Enterococcus faecium Infections – Pipeline Review, H2 2017’, provides an overview of the Vancomycin-Resistant Enterococcus faecium Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vancomycin-Resistant Enterococcus faecium Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Enterococcus faecium Infections

The report reviews pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Vancomycin-Resistant Enterococcus faecium Infections therapeutics and enlists all their major and minor projects

The report assesses Vancomycin-Resistant Enterococcus faecium Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus faecium Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Alchemia Ltd

Aphios Corp

C3J Therapeutics Inc

Helix BioMedix Inc

Hsiri Therapeutics LLC

LegoChem Biosciences Inc

MGB Biopharma Ltd

MicuRx Pharmaceuticals Inc

Nanotherapeutics Inc

NovoBiotic Pharmaceuticals LLC

Oragenics Inc

Ovensa Inc

Rebiotix Inc

Sealife PHARMA GMBH

Wockhardt Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Vancomycin-Resistant Enterococcus faecium Infections - Overview 8

Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 13

Products under Development by Companies 14

Products under Development by Universities/Institutes 16

Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Assessment 17

Assessment by Target 17

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Vancomycin-Resistant Enterococcus faecium Infections - Companies Involved in Therapeutics Development 25

Alchemia Ltd 25

Aphios Corp 25

C3J Therapeutics Inc 25

Helix BioMedix Inc 26

Hsiri Therapeutics LLC 26

LegoChem Biosciences Inc 27

MGB Biopharma Ltd 27

MicuRx Pharmaceuticals Inc 27

Nanotherapeutics Inc 28

NovoBiotic Pharmaceuticals LLC 28

Oragenics Inc 29

Ovensa Inc 29

Rebiotix Inc 29

Sealife PHARMA GMBH 30

Wockhardt Ltd 30

Vancomycin-Resistant Enterococcus faecium Infections - Drug Profiles 32

AM-218 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

BDM-I - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

chrysophaentin - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

closthioamide - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

contezolid acefosamil - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

HB-1345 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

HT-01 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

HT-02 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

IBN-1 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

LCB-010371 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Marinus - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

MGBBP-3 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

MRX-I - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

NAI-107 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

NAI-108 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

NAI-603 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

OG-253 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

ramoplanin - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

RBX-2660 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

SLP-0901 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

SLP-0904 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

SLP-0905 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

Small Molecule for Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus Infections - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

Small Molecules for Bacterial Infections - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

Small Molecules to Activate CLPP for Vancomycin Resistant Enterococci Infections - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Small Molecules to Inhibit Glycosyltransferase for Bacterial Infections - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Small Molecules to Target Bacterial Cell Wall for Vancomycin-Resistant Enterococcus faecium and Staphylococcus aureus Infections - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

Synthetic Peptides for Vancomycin Resistant Enterococci Infections - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

Teixobactin - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

WCK-4086 - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects 77

Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products 78

Vancomycin-Resistant Enterococcus faecium Infections - Product Development Milestones 79

Featured News & Press Releases 79

Nov 29, 2016: MicuRx Initiates Phase 1 Clinical Trial in U.S. for Novel Antibiotic Agent MRX-4 79

Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I 79

Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project 80

Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140 80

May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent 81

Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I 81

Appendix 83

Methodology 83

Coverage 83

Secondary Research 83

Primary Research 83

Expert Panel Validation 83

Contact Us 83

Disclaimer 84

List of Tables

List of Tables

Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H2 2017 9

Number of Products under Development by Companies, H2 2017 11

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 12

Number of Products under Development by Universities/Institutes, H2 2017 13

Products under Development by Companies, H2 2017 14

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15

Products under Development by Universities/Institutes, H2 2017 16

Number of Products by Stage and Target, H2 2017 18

Number of Products by Stage and Mechanism of Action, H2 2017 20

Number of Products by Stage and Route of Administration, H2 2017 22

Number of Products by Stage and Molecule Type, H2 2017 24

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Alchemia Ltd, H2 2017 25

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Aphios Corp, H2 2017 25

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by C3J Therapeutics Inc, H2 2017 26

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Helix BioMedix Inc, H2 2017 26

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Hsiri Therapeutics LLC, H2 2017 26

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by LegoChem Biosciences Inc, H2 2017 27

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by MGB Biopharma Ltd, H2 2017 27

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by MicuRx Pharmaceuticals Inc, H2 2017 28

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Nanotherapeutics Inc, H2 2017 28

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by NovoBiotic Pharmaceuticals LLC, H2 2017 28

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Oragenics Inc, H2 2017 29

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Ovensa Inc, H2 2017 29

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Rebiotix Inc, H2 2017 30

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Sealife PHARMA GMBH, H2 2017 30

Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Wockhardt Ltd, H2 2017 31

Vancomycin-Resistant Enterococcus faecium Infections – Dormant Projects, H2 2017 77

Vancomycin-Resistant Enterococcus faecium Infections – Discontinued Products, H2 2017 78

List of Figures

List of Figures

Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H2 2017 9

Number of Products under Development by Companies, H2 2017 10

Number of Products under Development by Universities/Institutes, H2 2017 13

Number of Products by Top 10 Targets, H2 2017 17

Number of Products by Stage and Top 10 Targets, H2 2017 17

Number of Products by Top 10 Mechanism of Actions, H2 2017 19

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 19

Number of Products by Routes of Administration, H2 2017 21

Number of Products by Stage and Routes of Administration, H2 2017 21

Number of Products by Molecule Types, H2 2017 23

Number of Products by Stage and Molecule Types, H2 2017 23

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports